Role of SALL4 in HER2+ breast cancer progression: Regulating PI3K/AKT pathway

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Pattanayak, Birlipta
• dc.contributor.author Lameirinhas, Ana
• dc.contributor.author Torres-Ruiz, Sandra
• dc.contributor.author Burgués, Octavio
• dc.contributor.author Rovira, Ana
• dc.contributor.author Martínez, María Teresa
• dc.contributor.author Tapia, Marta
• dc.contributor.author Zazo, Sandra
• dc.contributor.author Albanell Mestres, Joan
• dc.contributor.author Rojo, Federico
• dc.contributor.author Bermejo, Begoña
• dc.contributor.author Eroles, Pilar
• dc.date.accessioned 2023-04-13T06:23:28Z
• dc.date.available 2023-04-13T06:23:28Z
• dc.date.issued 2022
• dc.description.abstract Treatment for the HER2+ breast cancer subtype is still unsatisfactory, despite breakthroughs in research. The discovery of various new molecular mechanisms of transcription factors may help to make treatment regimens more effective. The transcription factor SALL4 has been related to aggressiveness and resistance therapy in cancer. Its molecular mechanisms and involvement in various signaling pathways are unknown in the HER2+ breast cancer subtype. In this study, we have evaluated the implication of SALL4 in the HER2+ subtype through its expression in patients' samples and gain and loss of function in HER2+ cell lines. We found higher SALL4 expression in breast cancer tissues compared to healthy tissue. Interestingly, high SALL4 expression was associated with disease relapse and poor patient survival. In HER2+ cell lines, transient overexpression of SALL4 modulates PI3K/AKT signaling through regulating PTEN expression and BCL2, which increases cell survival and proliferation while reducing the efficacy of trastuzumab. SALL4 has also been observed to regulate the epithelial-mesenchymal transition and stemness features. SALL4 overexpression significantly reduced the epithelial markers E-cadherin, while it increased the mesenchymal markers β-catenin, vimentin and fibronectin. Furthermore, it has been also observed an increased expression of MYC, an essential transcription factor for regulating epithelial-mesenchymal transition and/or cancer stem cells. Our study demonstrates, for the first time, the importance of SALL4 in the HER2+ subtype and partial regulation of trastuzumab sensitivity. It provides a viable molecular mechanism-driven therapeutic strategy for an important subset of HER2-overexpressing patients whose malignancies are mediated by SALL4 expression.
• dc.format.mimetype application/pdf
• dc.identifier.citation Pattanayak B, Lameirinhas A, Torres-Ruiz S, Burgués O, Rovira A, Martínez MT, Tapia M, Zazo S, Albanell J, Rojo F, Bermejo B, Eroles P. Role of SALL4 in HER2+ breast cancer progression: Regulating PI3K/AKT pathway. Int J Mol Sci. 2022 Oct 31;23(21):13292. DOI: 10.3390/ijms232113292
• dc.identifier.doi http://dx.doi.org/10.3390/ijms232113292
• dc.identifier.issn 1422-0067
• dc.identifier.uri http://hdl.handle.net/10230/56454
• dc.language.iso eng
• dc.publisher MDPI
• dc.relation.ispartof Int J Mol Sci. 2022 Oct 31;23(21):13292
• dc.rights © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/4.0/
• dc.subject.keyword EMT
• dc.subject.keyword HER2+ breast cancer
• dc.subject.keyword PI3K/AKT pathway
• dc.subject.keyword SALL4
• dc.title Role of SALL4 in HER2+ breast cancer progression: Regulating PI3K/AKT pathway
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion